Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naïve prostate cancer: The first real‐life experience in Asia

Poon, Darren M.C.; Chan, Tim; Chan, Kuen; Chan, Michelle; Lee, Eric K. C.; Law, Kitty; Lam, Dominic Man‐Kit

doi:10.1111/ajco.12874

Cited by 18 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rates of FN reported in randomized controlled trials ranged from 0.9% in TAX 327, 1 3% in GETUG‐AFU 15, 6 and 6.2% in CHAARTED, 3 to 15% in STAMPEDE 4 . Our previous real‐world data suggested that, compared with Western populations, Chinese patients may experience more frequent hematologic toxicities such as neutropenia, FN, and anaemia, 7 in accordance with genetic association findings on increased susceptibility to myelosuppression in Asian populations 8 . The rates of FN in these studies were 12.5% for patients with mHSPC who received docetaxel plus hormonal therapy, 7 and 14.0% for mCRPC patients treated with docetaxel‐based chemotherapy 8 .…”

Section: Introductionmentioning

confidence: 85%

“…Our previous real‐world data suggested that, compared with Western populations, Chinese patients may experience more frequent hematologic toxicities such as neutropenia, FN, and anaemia, 7 in accordance with genetic association findings on increased susceptibility to myelosuppression in Asian populations 8 . The rates of FN in these studies were 12.5% for patients with mHSPC who received docetaxel plus hormonal therapy, 7 and 14.0% for mCRPC patients treated with docetaxel‐based chemotherapy 8 . Similarly, a recent real‐world study in Korea reported an FN rate of 22.5% during the first cycle of docetaxel in mCRPC patients 9 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients

Poon

Chan

et al. 2021

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

IntroductionAsian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte colony‐stimulating factor (GCSF) for preventing FN in Chinese patients with metastatic hormone‐sensitive PC (mHSPC) and castration‐resistant PC (mCRPC).Patients and MethodsData from two cohorts of 377 Chinese patients with mHSPC (100; 26.5%) and mCRPC (277; 73.5%) treated with docetaxel at six public oncology centres were analysed with multivariate regression. Primary GCSF prophylaxis was defined as administration within 5 days of starting docetaxel. The primary outcome was FN within 21 days of the first docetaxel cycle (1st FN).ResultsPrimary GCSF was given to 71 (18.8%) patients. FN occurred in 61 patients (16.2%) including 37 (9.8%) during the first cycle. Among patients who developed 1st cycle FN (n = 37) or not (n = 340), 2 and 69 received primary GCSF (5.4 vs. 20.3%, P = .03). Primary GCSF was associated with an overall reduced risk of 1st cycle FN (odds ratio [OR] = 0.22; 95% confidence interval [CI]: 0.05‐0.96, P = .04), and similar trends were observed in the mHSPC (OR = 0.36, P = .35) and mCRPC (OR = 0.16, P = .08) subgroups. Poor Eastern Cooperative Oncology Group performance status (>1) was associated with an increased risk of 1st FN (OR = 3.90; 95% CI: 1.66‐9.13, P = .002).ConclusionsTo alleviate the risk of docetaxel‐related FN, primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status.

show abstract

Section: Introductionmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients

Poon

Chan

et al. 2021

Asia-Pac J Clncl Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although the relationships between genetic ethnic disparities and clinical outcomes in PC are somewhat unclear, the differences between Asian and White patients in chemotherapy tolerance have been well established. In our reports of real-world experience using docetaxel in Chinese patients with mHSPC as well as mCRPC, we found much higher incidences of haematological complications, particularly febrile neutropenia (FN), compared with studies in Western populations [ 22 , 23 , 24 , 25 ] ( Table 1 ). Furthermore, real-world data for cabazitaxel in international compassionate use and early access programmes revealed similarly elevated rates of myelosuppression among Asian patients [ 26 , 27 ].…”

Section: Drug Tolerability In Asian Patientsmentioning

confidence: 85%

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer

Poon

Chan

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Progression to metastatic disease occurs in about half of all men who develop prostate cancer (PC), one of the most common cancers in men worldwide. Androgen deprivation therapy has been the mainstay therapy for patients with metastatic PC (mPC) since the 1940s. In the last decade, there has been unprecedented advancement in systemic therapies, e.g., taxane, androgen-signalling pathway inhibitors, and biomarker-driven targeted therapies for various stages of disease, resulting in overall survival improvement. Adding to ongoing controversies over how best to treat these patients is the recognition that ethnicity may influence prognosis and outcomes. This review discusses recent evidence for the impacts of Asian ethnicity specifically, which includes environmental, sociocultural, and genetic factors, on the approach to pharmacological management of mPC. Clear inter-ethnic differences in drug tolerability, serious adverse events (AEs), and genetic heterogeneity must all be considered when dosing and scheduling for treatment, as well as designing future precision studies in PC.

show abstract

“…Forty-seven were removed as duplicates due to overlapping among databases. After screening the titles and abstracts and then the full texts, 27 publications 17 – 43 were shortlisted. No additional studies were identified from the bibliographic search.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review

et al. 2022

View full text Add to dashboard Cite

Objectives: Several therapies are available for the treatment of advanced/metastatic prostate cancer (PC). However, the systematic assessment of evidence pertaining to the use of these therapies in Asian patients is lacking. Methods: A systematic literature review (SLR) was conducted using PubMed/Medline search in May 2021 to identify the randomized/nonrandomized controlled trials (RCTs/non-RCTs) and real-world observational studies (prospective/retrospective). Only studies published as full manuscripts in English were included if reporting the efficacy, effectiveness, and/or safety of treatments in Asian patients with advanced/metastatic PC. Results: Of the 1,898 retrieved publications, 24 studies were included. These studies had patients with nonmetastatic castration-resistant PC (n = 2), metastatic castration-sensitive PC ( n = 4), and metastatic castration-resistant PC ( n = 18). Study designs included RCTs ( n = 7), non-RCTs ( n = 2), and real-world studies ( n = 15). Treatments used in included studies were abiraterone acetate plus prednisone (AAP; n = 6), enzalutamide, lutetium-177 prostate-specific membrane antigen (177Lu-PSMA; n = 4 each), docetaxel ( n = 3), apalutamide, radium-223 ( n = 2 each), darolutamide, cabazitaxel, and pembrolizumab ( n = 1 each). The evidence from RCTs (i.e., ARAMIS, SPARTAN, ARCHES, TITAN, LATITUDE, PREVAIL) demonstrated the clinical benefits of apalutamide, darolutamide, enzalutamide, and AAP in terms of overall, disease-free, and metastasis-free survival in Asian patients. These treatments were reported to be well tolerated, with no new safety signals identified in Asian population. The efficacy and safety profiles in Asian patients were consistent with the overall trial population. Data from real-world studies supported the effectiveness and tolerability of AAP, enzalutamide, radium-223, docetaxel, cabazitaxel, 177Lu-PSMA, and pembrolizumab in patients with advanced/metastatic PC. Conclusions: This SLR of the Asian data on therapies for advanced PC from the pivotal and real-world studies confirms similar efficacy and safety outcomes, consistent with the results from the pivotal clinical trials. These findings will help clinicians make better treatment decisions in clinical practice for patients with advanced/metastatic PC.

show abstract

Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naïve prostate cancer: The first real‐life experience in Asia

Cited by 18 publications

References 20 publications

Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients

Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer

Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review

Contact Info

Product

Resources

About